Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
Express Scripts
McKinsey
AstraZeneca

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR MIGALASTAT HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Migalastat Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00214500 ↗ A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-01-02 Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00283933 ↗ A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-05-09 Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00283959 ↗ A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-06-27 Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) and how migalastat works in participants with Fabry disease.
NCT00304512 ↗ A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-09-07 Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00526071 ↗ Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Terminated Amicus Therapeutics Phase 2 2007-09-17 Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
NCT00925301 ↗ Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease Completed Amicus Therapeutics Phase 3 2009-10-23 The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Migalastat Hydrochloride

Condition Name

Condition Name for Migalastat Hydrochloride
Intervention Trials
Fabry Disease 19
Fabry's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Migalastat Hydrochloride
Intervention Trials
Fabry Disease 20
Renal Insufficiency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Migalastat Hydrochloride

Trials by Country

Trials by Country for Migalastat Hydrochloride
Location Trials
United States 86
Australia 18
United Kingdom 11
Canada 10
France 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Migalastat Hydrochloride
Location Trials
Georgia 11
New York 8
Virginia 7
Pennsylvania 7
Texas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Migalastat Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Migalastat Hydrochloride
Clinical Trial Phase Trials
Phase 3 8
Phase 2 6
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Migalastat Hydrochloride
Clinical Trial Phase Trials
Completed 14
Terminated 2
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Migalastat Hydrochloride

Sponsor Name

Sponsor Name for Migalastat Hydrochloride
Sponsor Trials
Amicus Therapeutics 19
Genzyme, a Sanofi Company 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Migalastat Hydrochloride
Sponsor Trials
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Colorcon
McKinsey
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.